1. Home
  2. Health
  3. Type 2 Diabetes
photo of Debra Manzella, R.N.
Type 2 Diabetes Blog

By Debra Manzella, R.N., About.com Guide to Type 2 Diabetes

The Lancet Takes a Balanced View of Rosiglitazone Study

Sunday May 27, 2007

The online journal, The Lancet, published an editorial, May 23rd, 2007, on the current controversary surrounding the diabetes drug rosiglitazone (Avandia). The Lancet, established in 1823 in the UK, is a well-known authoritative medical journal. The editorial extends a voice of reason into the the fray concerning the recent study, published May 21, 2007, in the New England Journal of Medicine, which found an increase in heart attacks and other fatal cardiovascular conditions that appear to be caused by rosiglitazone.

The Lancet editorial recommends a "balanced" approach to the rosiglitazone study and states that although the findings do indicate that there is a need for concern, there were some "important weaknesses" in the study that need further investigation.

More from Dr. Rich, About.com's Heart Disease Guide...

Comments

No comments yet. Leave a Comment

Leave a Comment

Line and paragraph breaks are automatic. Some HTML allowed: <a href="" title="">, <b>, <i>, <strike>

Explore Type 2 Diabetes
About.com Special Features

Learn how you can reduce your your numbers with these nutrition and exercise tips. More >

Keep yourself, and your family, happy and healthy this fall with these tips. More >

  1. Home
  2. Health
  3. Type 2 Diabetes

©2009 About.com, a part of The New York Times Company.

All rights reserved.